CTOs on the Move

Won Ik Quartz Group

www.wiqg.com

 
Won Ik Quartz Group is a Gilroy, CA-based company in the Computers and Electronics sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.wiqg.com
  • 8100 Arroyo Cir
    Gilroy, CA USA 95020
  • Phone: 408.842.0103

Executives

Name Title Contact Details

Similar Companies

Kleer Corporation

Kleer Corporation is a Ottawa, ON-based company in the Computers and Electronics sector.

Lam Research

Lam Research Corp. (NASDAQ:LRCX) is a trusted global supplier of innovative semiconductor manufacturing equipment and services to the world’s leading chipmakers. Lam’s advanced process technology is transforming the way semiconductor devices are made, with atomic-scale features that are more than 1,000 times smaller than a grain of sand. We collaborate with customers to help them build smaller, faster, and more power-efficient devices that drive technology into everyday life. Lam focuses on solid product performance and value, continuous innovation, and a values-based culture that delivers on its commitments. It is why nearly every chip today is built with Lam technology.

Boston Circuits Inc

Boston Circuits Inc is a Woburn, MA-based company in the Computers and Electronics sector.

dsl labs

dsl labs is a Fremont, CA-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.